Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

6 months ago CAR-T

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients

China’s another cancer center launches an international medical department, offering comprehensive one-stop medical services to overseas patients.

cancer center

The International Medical Department of Tongji Hospital,

affiliated with Tongji University in Shanghai, has recently been officially launched. The department focuses on providing international medical services and aims to offer overseas patients a one-stop, seamless medical experience with high-quality and convenient healthcare services.

The advantages

of the International Medical Department at Tongji Hospital go beyond providing one-stop, comprehensive medical services to overseas patients. It also means that overseas patients can receive a full range of medical services, from initial consultation to treatment and recovery, all in one place, without the need for frequent referrals or seeking treatment across multiple hospitals. The department is equipped with advanced facilities and equipment, including PET-CT scanners, linear accelerators (LA), high-end MRI and CT scanners, DSA machines, as well as integrated hybrid operating rooms, laparoscopic surgery systems, and 4K3D high-definition laparoscopes, providing patients with state-of-the-art diagnostic and treatment methods.

Furthermore, as another cancer center in China

it offers the most advanced CAR-T cell therapy globally to all overseas patients. Tongji Hospital, well-known for its cancer treatment expertise in China, has accumulated rich experience and professional knowledge in the field of

CAR-T cell therapy

, enabling them to provide personalized and customized medical solutions for patients. The International Medical Department primarily serves high-end commercial insurance clients, foreign patients, overseas Chinese, diplomats and their families, and international corporate employees. The services provided by the department include initial consultation assessments, disease diagnosis, treatment plan development, surgeries and interventional therapies, rehabilitation, and follow-up care.

The medical team

is the core strength of the department. The International Medical Department at Tongji Hospital has recruited a team of foreign physicians, clinical experts, and returning young doctors from Tongji Hospital, covering almost all clinical specialties. In addition, the department regularly invites internationally renowned experts to visit, such as Professor Kurt Fritzsch, a professor of psychosomatic medicine at the University of Freiburg in Germany, and Professor Claus Cursiefen, a professor of ophthalmology at the University of Cologne in Germany. Especially as a cancer center in China, Tongji Hospital also has a team with the highest number of CAR-T cancer treatment cases worldwide, ensuring the provision of top-quality medical services to patients.

If patients are interested in seeking treatment in China

and staying at the International Medical Department of Tongji Hospital in Shanghai, or if they want to inquire about China’s cancer centers and the highest level of CAR-T therapy worldwide, the team at “Advanced medicine in China” will provide all the relevant services. These services include, but are not limited to, expert evaluations, online consultations with specialists, insurance service consultations, multilingual accompanying services, multilingual medical consultations and translation services, disease diagnosis, customized treatment plans, surgeries, interventional therapies, CAR-T treatments, hospitalization services, emergency rescue, referral services, medical companions, services for accompanying family members, and post-recovery guidance, among other value-added services, fully meeting the needs of patients.

WhatsApp: +86137 1795 9070

Email: doctor.huang@globecancer.com

7 months ago CAR-T

Success Story: Foreign Multiple Myeloma Patient Completes CAR-T Treatment at Chinese Hospital

A foreign multiple myeloma patient successfully completed CAR-T treatment at Jiahui International Hospital and was discharged with promising results.

Jiahui International Hospital

CAR-T therapy

short for “chimeric antigen receptor T-cell therapy,” represents a milestone in individualized cell immunotherapy for human cancers. It involves collecting the patient’s T-cells, genetically modifying them ex vivo to enhance their ability to recognize tumor cells specifically. These engineered “armed” T-cells (CAR-T cells) are then infused back into the patient to target and destroy tumor cells, while also forming memory T-cells for sustained anti-tumor effects. China has approved CAR-T therapy for lymphoma, multiple myeloma, and acute leukemia. The treatment process includes patient screening, bridging therapy, adverse reaction management, and long-term follow-up, requiring close collaboration among various teams, including hematology, cardiology, respiratory medicine, neurology, ICU, and experienced nursing teams.

The patient

an Australian residing in Shanghai, was diagnosed with multiple myeloma in 2008. Despite undergoing various treatments, including chemotherapy, immunotherapy, targeted therapy, and autologous stem cell transplantation, he unfortunately relapsed in 2022 with severe pain and bone damage. But due to the exorbitant cost of treatment in the United States, he has not been able to receive effective treatment.

IASO

BCMA-CAR-T

In July 2023, the BCMA-targeted Equecabtagene Autoleucel Injection developed by IASO Biotech was approved for marketing, specifically for the treatment of relapsed or refractory multiple myeloma adult patients who have undergone at least 3 prior lines of therapy. However, the price is only one-third of the treatment cost in the United States.

After consultation with Director Li Hua and Dr. Zhou Lili from the Hematology Team at Jiahui International Hospital, he decided to undergo this cutting-edge treatment at Jiahui. Throughout the treatment process, he continued working without interruption, only taking leave in the last three weeks for cell infusion, and the entire process went smoothly.

Choosing Jiahui International Hospital for CAR-T treatment not only avoided the hassle of extensive travel but also provided access to international standard medical services, efficient and convenient services, advanced therapies, and state-of-the-art facilities.

Since the approval of Chinese CAR-T therapy

China has established many high-level international CAR-T treatment teams, and more and more foreign and domestic hematologic tumor patients have chosen China for CAR-T treatment, including foreign lymphoma and multiple myeloma patients who have completed treatment and been discharged, as well as many patients from abroad who urgently need CAR-T treatment.

In the future, China will continue to explore innovative concepts and technologies for the clinical application, bringing new hope for cure to more hematologic tumor patients.

��To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

�� #CAR-T Success Story# �� #Jiahui International #Cancer Center# �� #International Collaboration# ��️ #Hope For Cure #Hope for patient #jiahui #cancer treatment

Menu

Tags Archives: Cancer Center